Apparently there's a plan to start vaccinating adults aged 50-74 here in Alberta, starting in April. I fall into two categories, for age and being at-risk. The idea is that we register by giving Alberta Health Services our email address and they'll email us when it's "our turn."
Going by this government's twisted priorities, I will be pleasantly surprised if they get around to me before the end of the year. I'll be even more pleasantly surprised if the site I'm told to go to will be somewhere I can actually get to.
Israeli studies find Pfizer COVID-19 vaccine reduces transmission
Data analysis in a study by the Israeli Health Ministry and Pfizer Inc found the Pfizer vaccine developed with Germany’s BioNTech reduces infection, including in asymptomatic cases, by 89.4% and in syptomatic cases by 93.7%.
[...]
A separate study by Israel’s Sheba Medical Center published on Friday in The Lancet medical journal found that among 7,214 hospital staff who received their first dose in January, there was an 85% reduction in symptomatic COVID-19 within 15 to 28 days with an overall reduction of infections, including asymptomatic cases detected by testing, of 75%.
It really gets me that serious journalists can quote a study without providing links to it. This BMJ article references these 2 papers, they sound a bit like it but it is from early Feb, so I guess not. I really wonder how they measure infectiousness of asymptomatic cases.
It really gets me that serious journalists can quote a study without providing links to it.
If I might ask, why?The NHS letter inviting me to apply for a vaccine arrived a few days ago, and my
local GP has texted me, but I will be putting the vaccination off for several weeks.
Canada seems to be behind the UK.
I suggest you explain your condition politely,
and have a para-medic sent to your home.
Ah, you haven't read Valka's posts on Stephen Harper then.We have always seen Canadians as practical unpretentious people with common sense.
They won't even vaccinate the staff of a hospital that specializes in treating extremely vulnerable cancer patients.